newsfilter
← Latest News
Business Wire·

BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor

BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC